CNTB Company Profile and Key Details

Q: Who are the executives of CNTB?

Mr. Steven ChanChief Financial OfficerDr. Chin Lee M.D., M.P.H.Chief Medical OfficerMr. Jiang Bian J.D.Gen. Counsel & Chief Compliance OfficerDr. Wubin Pan M.B.A., Ph.D.Co-Founder, Pres & Chairman of DirectorsDr. Raul Collazo Ph.D.Vice President & Global Head of Medical AffairsDr. Lei Sun Ph.D.Vice President of Biologics & Head of CMCDr. Malinda V. Longphre Ph.D.Vice President & Head of US Clinical OperationsDr. Zheng Wei Ph.D.Co-Founder, Chief Executive Officer & Director

NASDAQ : CNTB

Connect Biopharma

$2.37

0.06+2.60%

Open: 2:16 PM

61.88

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Connect Biopharma Holdings Limited (CNTB) stock surged +2.60%, trading at $2.37 on NASDAQ, up from the previous close of $2.31. The stock opened at $2.36, fluctuating between $2.28 and $2.40 in the recent session.

Stock Snapshot

2.31

Prev. Close

133.96M

Market Cap

2.28

Day Low

-2.06

P/E Ratio

-1.15

EPS (TTM)

-570.18

Cash Flow per Share

2.36

Open

56.52M

Number of Shares

2.4

Day High

25.74%

Free Float in %

1834.41

Book Value

62.81K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
May 20, 2026	2.21	2.38	2.19	2.31	201.29K
May 19, 2026	2.34	2.34	2.19	2.19	129.91K
May 18, 2026	2.39	2.42	2.33	2.38	130.73K
May 15, 2026	2.42	2.48	2.33	2.38	113.2K
May 14, 2026	2.48	2.59	2.40	2.48	160.23K
May 13, 2026	2.59	2.70	2.43	2.45	210.43K
May 12, 2026	2.38	2.69	2.36	2.68	230.27K
May 11, 2026	2.36	2.42	2.32	2.34	115.06K
May 08, 2026	2.33	2.40	2.27	2.36	95.04K
May 07, 2026	2.44	2.48	2.30	2.33	127.51K
May 06, 2026	2.47	2.55	2.44	2.48	67.47K
May 05, 2026	2.51	2.59	2.43	2.47	218.96K
May 04, 2026	2.46	2.60	2.45	2.48	187.38K
Apr 30, 2026	2.57	2.57	2.42	2.47	102.43K
Apr 29, 2026	2.43	2.56	2.33	2.53	124.87K
Apr 28, 2026	2.46	2.50	2.35	2.40	148.41K
Apr 27, 2026	2.51	2.59	2.44	2.45	142.2K
Apr 23, 2026	2.60	2.65	2.47	2.52	228.37K
Apr 22, 2026	2.65	2.71	2.57	2.60	216.43K
Apr 21, 2026	2.72	2.82	2.55	2.58	455.67K

Contact Details

Taicang, 215400

China

https://www.connectbiopharm.com 865 125 3577866

About Company

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, a regulator of T cell mobilization out of lymph nodes into the periphery that is in Phase II for the treatment of autoimmune-related inflammation diseases; CBP-174, a small molecule histamine receptor 3 antagonist for oral administration, which is in a preclinical stage to treat chronic itch associated with skin inflammation; and CBP-233, a preclinical stage humanized antibody against interleukin-33, a cytokine involved in T helper 2 inflammation. The company was founded in 2012 and is headquartered in Taicang, China.

Stock Peers

ARGX

6.48+0.81%

argenx SE$804.25 REGN

19.46+3.09%

Regeneron Pharmaceuticals, Inc.$649.76 UTHR

-2.87-0.51%

United Therapeutics Corporation$563.93 MDGL

1.65+0.32%

Madrigal Pharmaceuticals, Inc.$513.47 VRTX

-3.87-0.89%

Vertex Pharmaceuticals Incorporated$430.44 PRAX

15+4.68%

Praxis Precision Medicines, Inc.$335.61 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 KRYS

8.75+2.98%

Krystal Biotech, Inc.$302.05 ALNY

4.18+1.42%

Alnylam Pharmaceuticals, Inc.$298.48 ASND

3.36+1.41%

Ascendis Pharma A/S$241.34

Company Overview

Connect Biopharma Holdings Limited (NASDAQ:CNTB) closed at $2.37 USD, gaining $0.06 (2.60%) from the previous close of $2.31. The stock is currently mid-range between its 52-week high and low $0.72 and $3.82. With a market capitalization of about $133.96 million, Connect Biopharma Holdings Limited is classified as a micro-cap and shows lower-than-market volatility (beta ~-0.20). Key stats such as the average daily volume over the past year has been around 259.25 thousand shares, volume is running light vs its 52-week average. Headquartered in Taicang, None, Connect Biopharma Holdings Limited operates in the Healthcare sector and the Biotechnology industry. Led by CEO Barry D. Quart, the company employs approximately 62 people and listed since March 19, 2021. Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation.

Technical Performance

CNTB has shown sold momentum, gaining 8.49% over the past week and 32.95% over the past quarter, though year-to-date performance is down -18.44%. Short-term trend indicators are bearishly aligned (SMA20 -2.55%, SMA50 1.24%, SMA200 35.07%). The stock’s 14-day RSI is 48.59 (neutral), while the ATR of 0.25 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -23.17% below its high and over 394.12% above its low. Average 10-day trading volume of 161.39 thousand shares is below the 3-month average of 251.87 thousand, indicating normal recent market interest.

Valuation Metrics

Connect Biopharma Holdings Limited trades at a P/E ratio of -4.63, slightly below the S&P 500 average, with a price-to-sales ratio of 2743.64 and a price-to-book ratio of 3.09 trading at moderately above to book value. The P/FCF stands at -5.45, also above market averages.

Dividend & Fair Value

Connect Biopharma Holdings Limited last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.68. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Connect Biopharma Holdings Limited generated EPS of -$0.28 over the past year. Five-year average earnings growth is 7.78%. The latest quarter delivered EPS of -$0.05. The next quarter is forecast at -$0.30. Next year's EPS is expected at $97.80. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 6 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $10.00 to $4.00. The high target offers 332.9% upside. The low target suggests 73.16% downside. The mean target is $8.57. This offers 271.0% upside. Connect Biopharma Holdings Limited earnings surprise history is frequent misses against expectations. The quarter that ended May 12, 2026, missed forecasts by -81.75%. The prior quarter beat by -10.0%. Over the last six quarters, Apple has recorded several small beats. These include -133.73% in September 05, 2024.

Shareholding & Insider Activity

Connect Biopharma Holdings Limited has 55.72 million shares outstanding. The public float is 14.34 million shares, elevated short interest at 0.29% of float. This equals 102.42 thousand shares. The short ratio is 0.44 days. Institutional investors hold 74.4% of the float. Insiders own 40.53%. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Connect Biopharma has not generated any revenue. Returns are negative, with ROA at -65.77% and ROE at 25.10%.
On valuation metrics, Connect Biopharma trades at a P/E of -4.63, P/S of 2743.64 and P/B of 3.09. The current ratio is 3.74 and quick ratio is 3.74. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is 1224.27 days. Debt-to-equity is 0.02, supported by a cash flow-to-debt ratio of -34.55.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2022, Connect Biopharma posted revenue of $0.00, down slightly from $0.00 in the prior quarter. Operating income was - $805.59M (margin 0.0%). Net income was- $797.06M (EPS - $14.50).
The company ended the quarter with $1.13B in cash and short-term investments, a total debt of $3.00M, and net debt of - $547.28M. Total assets were $1.21B, with equity of - $3.18B. Financials further reflected weakness, with operating cash flow of - $47.93M, free cash flow of - $48.22M, and capital expenditures of - $294.00K.

Price Forecast & Outlook

Our AI price prediction model suggests that Connect Biopharma Holdings Limited stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -11.26%, with price expected at $2.05 by June 03, 2026, within a range of $1.86 to $2.24 3-Month Outlook: Projected rise of 72.29%, reaching $3.98 by August 18, 2026, with a range of $3.92 to $4.05. 1-Year Outlook: Projected gain of 363.64%, with price at $10.71 by May 20, 2027, within a range of $5.11 to $15.78.

Key Takeaways

Connect Biopharma Holdings Limited (NASDAQ:CNTB) shares are down -18.44% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Connect Biopharma Holdings Limited trading at a premium to the broader market with a P/E of -4.63. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $9.77, suggesting 322.94% upside. Our AI forecast model points to short-term weakness (-11.26% over two weeks), a medium-term rise (72.29% over three months), and a longer-term gain (363.64% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Connect Biopharma Holdings Limited (CNTB) stock price?

Connect Biopharma Holdings Limited (NASDAQ: CNTB) stock price is $2.37 in the last trading session. During the trading session, CNTB stock reached the peak price of $2.40 while $2.28 was the lowest point it dropped to. The percentage change in CNTB stock occurred in the recent session was 2.6% while the dollar amount for the price change in CNTB stock was $0.06.

CNTB's industry and sector of operation?

The NASDAQ listed CNTB is part of Biotechnology industry that operates in the broader Healthcare sector. Connect Biopharma Holdings Limited designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of CNTB?

Mr. Steven Chan
Chief Financial Officer
Dr. Chin Lee M.D., M.P.H.
Chief Medical Officer
Mr. Jiang Bian J.D.
Gen. Counsel & Chief Compliance Officer
Dr. Wubin Pan M.B.A., Ph.D.
Co-Founder, Pres & Chairman of Directors
Dr. Raul Collazo Ph.D.
Vice President & Global Head of Medical Affairs
Dr. Lei Sun Ph.D.
Vice President of Biologics & Head of CMC
Dr. Malinda V. Longphre Ph.D.
Vice President & Head of US Clinical Operations
Dr. Zheng Wei Ph.D.
Co-Founder, Chief Executive Officer & Director

How CNTB did perform over past 52-week?

CNTB's closing price is 220.83% higher than its 52-week low of $0.72 where as its distance from 52-week high of $3.82 is -39.53%.

How many employees does CNTB have?

Number of CNTB employees currently stands at 62.

Link for CNTB official website?

Official Website of CNTB is: https://www.connectbiopharm.com

How do I contact CNTB?

CNTB could be contacted at phone 865 125 3577866 and can also be accessed through its website. CNTB operates from East R&D Building, Taicang, 215400, China.

How many shares of CNTB are traded daily?

CNTB stock volume for the day was 62.81K shares. The average number of CNTB shares traded daily for last 3 months was 259.25K.

What is the market cap of CNTB currently?

The market value of CNTB currently stands at $133.96M with its latest stock price at $2.37 and 56.52M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	62
Beta	-0.19
Sales or Revenue	$0.00
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

CNTB Company Profile and Key Details

Connect Biopharma

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways